Log in

NYSE:AIMAIM ImmunoTech Stock Price, Forecast & News

$2.99
+0.07 (+2.40 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.82
Now: $2.99
$3.10
50-Day Range
$2.35
MA: $2.75
$3.88
52-Week Range
$0.38
Now: $2.99
$7.11
Volume6.54 million shs
Average Volume8.85 million shs
Market Capitalization$97.53 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.83
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone352-448-7797

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$140,000.00
Book Value$1.47 per share

Profitability

Net Income$-9,530,000.00
Net Margins-5,392.43%

Miscellaneous

Employees31
Market Cap$97.53 million
Next Earnings Date8/20/2020 (Estimated)
OptionableNot Optionable
$2.99
+0.07 (+2.40 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AIM News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AIM ImmunoTech (NYSE:AIM) Frequently Asked Questions

How has AIM ImmunoTech's stock been impacted by COVID-19 (Coronavirus)?

AIM ImmunoTech's stock was trading at $4.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AIM shares have decreased by 28.8% and is now trading at $2.99.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of AIM ImmunoTech?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AIM ImmunoTech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AIM ImmunoTech
.

When is AIM ImmunoTech's next earnings date?

AIM ImmunoTech is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020.
View our earnings forecast for AIM ImmunoTech
.

How were AIM ImmunoTech's earnings last quarter?

AIM ImmunoTech Inc. (NYSE:AIM) released its earnings results on Wednesday, May, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.13. The firm had revenue of $0.05 million for the quarter. AIM ImmunoTech had a negative return on equity of 61.52% and a negative net margin of 5,392.43%.
View AIM ImmunoTech's earnings history
.

What price target have analysts set for AIM?

2 equities research analysts have issued 12 month price targets for AIM ImmunoTech's shares. Their forecasts range from $4.00 to $5.00. On average, they expect AIM ImmunoTech's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 50.5% from the stock's current price.
View analysts' price targets for AIM ImmunoTech
.

Has AIM ImmunoTech been receiving favorable news coverage?

Media stories about AIM stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AIM ImmunoTech earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about AIM ImmunoTech
.

Who are some of AIM ImmunoTech's key competitors?

What other stocks do shareholders of AIM ImmunoTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Vaxart (VXRT), SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP), Ibio (IBIO), Novavax (NVAX), Canopy Growth (CGC), Pfizer (PFE) and Nokia Oyj (NOK).

Who are AIM ImmunoTech's key executives?

AIM ImmunoTech's management team includes the following people:
  • Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 66)
  • Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 68)
  • Mr. Adam Pascale, Consultant (Age 71)
  • Mr. Wayne S. Springate, Sr. VP of Operations (Age 48)
  • Ms. Ellen Lintal, Chief Accounting Officer

What is AIM ImmunoTech's stock symbol?

AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM."

Who are AIM ImmunoTech's major shareholders?

AIM ImmunoTech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.20%), SeaCrest Wealth Management LLC (0.14%) and Stanley Laman Group Ltd. (0.04%). Company insiders that own AIM ImmunoTech stock include David R Strayer, Thomas K Equels, Wayne S Springate and William M Mitchell.
View institutional ownership trends for AIM ImmunoTech
.

Which institutional investors are buying AIM ImmunoTech stock?

AIM stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC, SeaCrest Wealth Management LLC, and Stanley Laman Group Ltd.. Company insiders that have bought AIM ImmunoTech stock in the last two years include David R Strayer, Thomas K Equels, Wayne S Springate, and William M Mitchell.
View insider buying and selling activity for AIM ImmunoTech
.

How do I buy shares of AIM ImmunoTech?

Shares of AIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AIM ImmunoTech's stock price today?

One share of AIM stock can currently be purchased for approximately $2.99.

How big of a company is AIM ImmunoTech?

AIM ImmunoTech has a market capitalization of $97.53 million and generates $140,000.00 in revenue each year. AIM ImmunoTech employs 31 workers across the globe.

What is AIM ImmunoTech's official website?

The official website for AIM ImmunoTech is aimimmuno.com.

How can I contact AIM ImmunoTech?

AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The company can be reached via phone at 352-448-7797 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.